File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Sirolimus in kidney transplantation: A pilot study in Chinese patients
  • Basic View
  • Metadata View
  • XML View
TitleSirolimus in kidney transplantation: A pilot study in Chinese patients
 
AuthorsLam, MF1
Yip, TPS1
Tse, KC1
Li, FK1
Lui, SL1
Lai, KN1
Chan, TM1
 
KeywordsChinese population
Hyperlipidemia
Kidney transplantation
Sirolimus
 
Issue Date2004
 
PublisherLippincott Williams & Wilkins Asia. The Journal's web site is located at http://www.hkjn.org/
 
CitationHong Kong Journal Of Nephrology, 2004, v. 6 n. 1, p. 38-42 [How to Cite?]
 
AbstractWe conducted a pilot open-label study on the use of sirolimus in 10 Chinese patients undergoing kidney transplantation who received triple prophylactic immunosuppression comprising prednisolone, cyclosporine and sirolimus. Sirolimus was given as a 6 mg loading dose followed by 2 mg/day maintenance. All patients achieved target sirolimus trough serum concentrations exceeding 5 ng/mL. Median duration of follow-up was 22 months after transplantation. One patient developed Type Ia acute cellular rejection at 6 months, which responded to pulse steroid therapy. Graft survival was 100% at 12 months and serum creatinine was 131 ± 36 μmol/L at 1 year. Low-density lipoprotein cholesterol and triglyceride levels were significantly increased after 2 months. Eight patients received atorvastatin, which was subsequently discontinued successfully in three patients. Infection was noted in two patients; one died of pneumocystis pneumonia 10 months after transplantation and the other had septicemia from urinary tract infection complicating graft vesicoureteric reflux. Two patients developed lymphocele in the early postoperative period, which resolved spontaneously in one patient and was treated successfully with ethanol sclerotherapy in the other. No patients developed thrombocytopenia or arthralgia. We conclude that sirolimus, when used together with prednisolone and cyclosporine, is well tolerated and effective in Chinese renal allograft recipients, and that hyperlipidemia early after transplantation is the most common adverse effect.
 
ISSN1561-5413
2012 SCImago Journal Rankings: 0.162
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorLam, MF
 
dc.contributor.authorYip, TPS
 
dc.contributor.authorTse, KC
 
dc.contributor.authorLi, FK
 
dc.contributor.authorLui, SL
 
dc.contributor.authorLai, KN
 
dc.contributor.authorChan, TM
 
dc.date.accessioned2010-09-06T07:30:29Z
 
dc.date.available2010-09-06T07:30:29Z
 
dc.date.issued2004
 
dc.description.abstractWe conducted a pilot open-label study on the use of sirolimus in 10 Chinese patients undergoing kidney transplantation who received triple prophylactic immunosuppression comprising prednisolone, cyclosporine and sirolimus. Sirolimus was given as a 6 mg loading dose followed by 2 mg/day maintenance. All patients achieved target sirolimus trough serum concentrations exceeding 5 ng/mL. Median duration of follow-up was 22 months after transplantation. One patient developed Type Ia acute cellular rejection at 6 months, which responded to pulse steroid therapy. Graft survival was 100% at 12 months and serum creatinine was 131 ± 36 μmol/L at 1 year. Low-density lipoprotein cholesterol and triglyceride levels were significantly increased after 2 months. Eight patients received atorvastatin, which was subsequently discontinued successfully in three patients. Infection was noted in two patients; one died of pneumocystis pneumonia 10 months after transplantation and the other had septicemia from urinary tract infection complicating graft vesicoureteric reflux. Two patients developed lymphocele in the early postoperative period, which resolved spontaneously in one patient and was treated successfully with ethanol sclerotherapy in the other. No patients developed thrombocytopenia or arthralgia. We conclude that sirolimus, when used together with prednisolone and cyclosporine, is well tolerated and effective in Chinese renal allograft recipients, and that hyperlipidemia early after transplantation is the most common adverse effect.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationHong Kong Journal Of Nephrology, 2004, v. 6 n. 1, p. 38-42 [How to Cite?]
 
dc.identifier.epage42
 
dc.identifier.hkuros99092
 
dc.identifier.issn1561-5413
2012 SCImago Journal Rankings: 0.162
 
dc.identifier.issue1
 
dc.identifier.openurl
 
dc.identifier.scopuseid_2-s2.0-2342623354
 
dc.identifier.spage38
 
dc.identifier.urihttp://hdl.handle.net/10722/77307
 
dc.identifier.volume6
 
dc.languageeng
 
dc.publisherLippincott Williams & Wilkins Asia. The Journal's web site is located at http://www.hkjn.org/
 
dc.publisher.placeHong Kong
 
dc.relation.ispartofHong Kong Journal of Nephrology
 
dc.relation.referencesReferences in Scopus
 
dc.subjectChinese population
 
dc.subjectHyperlipidemia
 
dc.subjectKidney transplantation
 
dc.subjectSirolimus
 
dc.titleSirolimus in kidney transplantation: A pilot study in Chinese patients
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Lam, MF</contributor.author>
<contributor.author>Yip, TPS</contributor.author>
<contributor.author>Tse, KC</contributor.author>
<contributor.author>Li, FK</contributor.author>
<contributor.author>Lui, SL</contributor.author>
<contributor.author>Lai, KN</contributor.author>
<contributor.author>Chan, TM</contributor.author>
<date.accessioned>2010-09-06T07:30:29Z</date.accessioned>
<date.available>2010-09-06T07:30:29Z</date.available>
<date.issued>2004</date.issued>
<identifier.citation>Hong Kong Journal Of Nephrology, 2004, v. 6 n. 1, p. 38-42</identifier.citation>
<identifier.issn>1561-5413</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/77307</identifier.uri>
<description.abstract>We conducted a pilot open-label study on the use of sirolimus in 10 Chinese patients undergoing kidney transplantation who received triple prophylactic immunosuppression comprising prednisolone, cyclosporine and sirolimus. Sirolimus was given as a 6 mg loading dose followed by 2 mg/day maintenance. All patients achieved target sirolimus trough serum concentrations exceeding 5 ng/mL. Median duration of follow-up was 22 months after transplantation. One patient developed Type Ia acute cellular rejection at 6 months, which responded to pulse steroid therapy. Graft survival was 100% at 12 months and serum creatinine was 131 &#177; 36 &#956;mol/L at 1 year. Low-density lipoprotein cholesterol and triglyceride levels were significantly increased after 2 months. Eight patients received atorvastatin, which was subsequently discontinued successfully in three patients. Infection was noted in two patients; one died of pneumocystis pneumonia 10 months after transplantation and the other had septicemia from urinary tract infection complicating graft vesicoureteric reflux. Two patients developed lymphocele in the early postoperative period, which resolved spontaneously in one patient and was treated successfully with ethanol sclerotherapy in the other. No patients developed thrombocytopenia or arthralgia. We conclude that sirolimus, when used together with prednisolone and cyclosporine, is well tolerated and effective in Chinese renal allograft recipients, and that hyperlipidemia early after transplantation is the most common adverse effect.</description.abstract>
<language>eng</language>
<publisher>Lippincott Williams &amp; Wilkins Asia. The Journal&apos;s web site is located at http://www.hkjn.org/</publisher>
<relation.ispartof>Hong Kong Journal of Nephrology</relation.ispartof>
<subject>Chinese population</subject>
<subject>Hyperlipidemia</subject>
<subject>Kidney transplantation</subject>
<subject>Sirolimus</subject>
<title>Sirolimus in kidney transplantation: A pilot study in Chinese patients</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=1561-5413&amp;volume=6&amp;issue=1&amp;spage=38&amp;epage=42&amp;date=2004&amp;atitle=Sirolimus+in+kidney+transplantation:+a+pilot+study+in+Chinese+patients</identifier.openurl>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.scopus>eid_2-s2.0-2342623354</identifier.scopus>
<identifier.hkuros>99092</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-2342623354&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>6</identifier.volume>
<identifier.issue>1</identifier.issue>
<identifier.spage>38</identifier.spage>
<identifier.epage>42</identifier.epage>
<publisher.place>Hong Kong</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong